BBMCT has a long history of running successful trials in the CKD space, and we’ve used that time to become true experts in nephrology trials. We’ve built deep and lasting relationships with respected nephrologists and nephrology key opinion leaders. BBMCT conducts trials in renally-impaired patients, including patients currently undergoing dialysis, and in patients suffering from other chronic and rare kidney diseases.
Our scientifically-driven approach to clinical development provides you the advantage of early and ongoing insight and guidance from therapeutic experts throughout trial design and execution. Understanding that renal patients often have comorbidities such as cardiovascular disease, diabetes, and obesity, our nephrology and renal disease team works in collaboration with our in-house experts in these associated diseases. Our model embeds scientific expertise throughout your studies, providing greater depth and the ability to tackle complex and challenging diseases.
Nephrology and Renal Disease clinical trials include diverse patient populations with complex diagnoses and comorbidities, which can bring with them both high costs and patient recruitment shortfalls. Familiarity with finding and managing these patients is key to study management as well as site selection.
At BBMCT, we understand the unique challenges of nephrology and urology studies and know how to simplify and streamline your experience with a collaborative team, consortia partnerships, and state-of-the-art technology.
- Renal insufficiency and failure
- Genetic or Rare kidney diseases including Vasculitis and Enteric Hyperoxaluria
- Glomerulonephritis associated with ANCA vasculitis, IgA nephropathy, membranous nephropathy, C3 glomerulonephritis and focal segmental Glomerulosclerosis
- Bone & Mineral Metabolism (including hyperphosphatemia)
- Metabolic acidosis/alkalosis, electrolyte Disorders
- Diabetic Nephropathy
- Acute kidney injury
- Chronic kidney failure
- Diabetic kidney disease
- Autoimmune diseases, including lupus nephritis
- Polycystic kidney disease, autosomal dominant
- End stage renal disease
- Peritoneal dialysis
- Anemia of CKD, including iron supplements and erythropoiesis-stimulating agents
- Renal bone disease and secondary hyperparathyroidism, including phosphate binding agents, calcimimetics, and vitamin D analogues
- Arterial calcification
- Hemodialysis access, including catheter lock solutions
- Renal cell carcinoma
- Transplantation, including immunosuppressive therapy
- Other orphan diseases, including:
- Lysosomal storage diseases
- Fabry disease
- Adrenal gland neoplasms
- Renal artery obstruction